The FDA Has Removed Clinical Hold From Pharvaris' Investigational New Drug Application For Deucrictibant For The On-demand Treatment Of Hereditary Angioedema
Portfolio Pulse from Benzinga Newsdesk
The FDA has lifted the clinical hold on Pharvaris' Investigational New Drug (IND) application for Deucrictibant, an on-demand treatment for Hereditary Angioedema.
June 26, 2023 | 10:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pharvaris' IND application for Deucrictibant has been cleared by the FDA, potentially benefiting the company's stock in the short term.
The FDA lifting the clinical hold on Pharvaris' IND application for Deucrictibant is a positive development for the company. This allows Pharvaris to proceed with clinical trials and brings the drug closer to potential approval and commercialization, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100